Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies.

DG scores for bevacizumab monotherapy patients only approached significance for PFS.

also in 8,237 other papers

Prior and Median DG T1Gd scores for BevCyto patients were highly significant for both OS and PFS in Kaplan–Meier analysis log-rank tests ( Table 2 , Figure 2 , and Supplementary Figure 1E–F ).

also in 132,142 other papers